[Peptide vaccination therapy for malignant glioma].
Despite advances in radiation and chemotherapy along with surgical resectioning, the prognosis of patients with malignant glioma is poor. Therefore, the development of a new treatment modality is extremely important. There are increasing reports demonstrating that systemic immunotherapy using peptide is capable of inducing an antiglioma response. This review highlights peptide-based immunotherapy for glioma patients. Peptide-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma. Peptide-based therapy of glioma seems to be safe and without major side effects. Biotherapy for malignant glioma with peptide will open a novel reality now.
Yamanaka
Ryuya
R
Research Center of Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan.
Itoh
Kyogo
K
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002490:Central Nervous System / Q000276:immunology; D005910:Glioma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D016233:Immunotherapy, Active; D022223:Vaccines, Subunit / Q000627:therapeutic use*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D022223:Vaccines, Subunit